Millennium Management
VIRX

Millennium Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Millennium Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,366
Closed -$5.05M – 4337
2014
Q3 		$5.05M Buy
+3,366
New +$4.87M 0.01% 1282

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management's VIRX Position: Q4 2023 in Review

Millennium Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2023, closing a stake of 36,533 shares — an estimated $38K sold.

Millennium Management first reported a position in VIRX in Q2 2013 and held it in 27 quarters. The position peaked at $7.33M in Q2 2013. 42 funds tracked by Wall St. Rank hold VIRX as of Q4 2023.

  • Millennium Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Millennium Management sold 36,533 Viracta Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $38K.
  • Millennium Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Millennium Management's Viracta Therapeutics, Inc. Common Stock position peaked at $7.33M in Q2 2013.
  • 42 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.